Status:
UNKNOWN
The Clinical Value of FA in AHLRI Patients
Lead Sponsor:
Bin Cao
Collaborating Sponsors:
BioMérieux
Conditions:
Lower Respiratory Tract Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
LRTI (Lower respiratory tract infection) is a severe disease in China. The fast and accurate diagnosis of pathogens, bacteria or viruses that cause the infection is critical for the therapy. In this s...
Eligibility Criteria
Inclusion
- Adults age \>= 18 years old
- Community acquired Pneumonia, acute exacerbation of chronic obstructive pulmonary disease \[AECOPD\], acute exacerbation of bronchiectasis.
- Hospitalization required
- Informed Consent Form signed
Exclusion
- Age \< 18 years old
- Hospital acquired Pneumonia
- Patients with lung tuberculosis
- Pregnant women
- Patients with immunodeficiency
- Any conditions which may increase PCT levels
- Informed Consent Form not signed
Key Trial Info
Start Date :
September 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 23 2018
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT03391076
Start Date
September 21 2017
End Date
October 23 2018
Last Update
October 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chian Japan Friendship Hospital
Beijing, Beijing Municipality, China